How We Collaborate With Patient Organisations
Boehringer Ingelheim’s core principles and vision guide our work with patient organisations. We are committed to the goal of serving humankind through research into diseases and the development of new medicines and therapies.
Our Mission
Be a trusted partner for patient organisations and those they represent in the development of innovative medicines, education and services that improve patients' lives.
Aims of Our Collaboration
We are committed to working collaboratively with patient organisations that support the needs of patients, their families and/or caregivers. This offers an opportunity for us to learn from each other in order to:
- Understand the needs and expectations patients, their families and their caregivers have, and the challenges they face in the current therapeutic and healthcare environments
- Include the perspectives and needs of patients, their families and caregivers in the development of our medicines, clinical trials and patient support services
- Increase patient satisfaction with our clinical trials and medicines
- Increase disease awareness and improve patient education
- Support patient access to medicines and healthcare services
- Understand and support the objectives of patient organisations throughout the course of the patient’s disease
Our Guiding Principles
We believe true collaborations with patient organisations contribute to advances in research and healthcare innovation to serve patients, their families and caregivers by improving their health and quality of life.
These collaborations reflect Boehringer Ingelheim’s core values we believe in: Respect, Trust, Empathy and Passion, and are guided by the following principles:
- We comply with any applicable laws, regulations and industry codes regulating the relationship between the pharmaceutical industry and patient organisations such as the EFPIA and FSA codices.
- We work with patient organisations in an open, transparent and ethical manner.
- We fully respect the views and independence of patient organisations, considering them as equal and valued partners with knowledge and experiences that Boehringer Ingelheim wishes to understand.
- Collaborations between Boehringer Ingelheim and patient organisations are chosen on the basis of mutual goals with the aim to serve patient needs.
- We engage with patient organisations and we are committed to establishing collaborations over the longer term.
- We strive to provide information to patient organisations that is fully informed, accurate, easy-to-understand, and presented in a balanced way in order to help patient organisations achieve their goals.
- We will engage with representatives of patient organisations who will serve as advisors, members of patient advisory boards, or speakers, for the purpose of supporting healthcare and research.
- We will provide reasonable financial or non-financial support to patient organisations.
- We encourage patient organisations to have a diverse range of funding sources and long-term strategy.
- We encourage patient organisations to be transparent on their funding sources.
- We do not request, expect, ask or encourage patient organisations to promote or support the usage of any specific product over another.
- Any project collaboration with a patient organisation is based on a written agreement that clearly states the nature, purpose and duration of the activity, as well as any support (either financial or non-financial support) provided by Boehringer Ingelheim.
- We report accurate, fair and objective information about our collaboration with patient organisations in a transparent manner.
- We fully respect the privacy of personal data and do not expect patient organisations to provide any personal patient or family information.
Our Partners and Patient Advocacy Relations Function
Boehringer Ingelheim has been engaging with patient organisations over more than fifteen years through its global affiliates and its corporate organisation. In 2015 we created a global patient advocacy relations function to further coordinate our collaborations and activities with patient organisations.
During our project collaborations with patient organisations Boehringer Ingelheim’s Corporate Organisation (Boehringer Ingelheim GmbH) has provided financial and non-financial contributions to the following patient organisations:
Contributions
2017
| Name of Patient Organisation | Nature of support | Amount |
|---|---|---|
| Action for Pulmonary Fibrosis (APF), Bury St. Edmunds, UK | Travel expenses for representative planned to attend Patient Organisation Advisory Board Meeting | 103 EUR |
| Action for Pulmonary Fibrosis (APF), Bury St. Edmunds, UK | Travel expenses for representative attending Patient Organisation Advisory Board Meeting and consulting fee paid to organisation | 428 EUR |
| Alzheimer Disease International (ADI), London, UK | Travel expenses for ADI representatives and representatives of ADI member organisations attending Advisory Board Meeting and consulting fees paid to organisation | 26,497 EUR |
| Asociación de Familiares y Enfermos de Fibrosis Pulmonar Idiopática (AFEFPI), Madrid, Spain | Travel expenses for representatives attending Patient Organisation Advisory Board Meetings | 747 EUR |
| Association Française des Polyarthritiques Et des Rhumatismes Inflammatoires Chroniques (AFPric), Paris, France | Travel expenses for representative attending Patient Organisation Advisory Board Meeting | 709 EUR |
| Association Française des Polyarthritiques Et des Rhumatismes Inflammatoires Chroniques (AFPric), Paris, France | Sponsorship of "survey for patients with rheumatoid arthritis about interstitial lung disease" | 5,000 EUR |
| Association Nationale de Défense contre l'Arthrite Rhumatoïde (ANDAR), Paris, France | Travel expenses for representative attending Patient Organisation Advisory Board Meeting | 541 EUR |
| Association Pierre Enjalran Fibrose Pulmonaire Idiopathique (APEFPI), Ardiège, France | Travel expenses for representatives attending Patient Organisation Advisory Board Meetings and consulting fees paid to organisation | 488 EUR |
| Atrial Fibrillation Association (AFA), Chipping Norton, UK | Consulting fee paid to organisation for participation in facebook live broadcast “Taking control of AF together” | 510 GBP |
| Atrial Fibrillation Association (AFA), Chipping Norton, UK | Consulting fee for support to develope an opinion piece in form of a question and answer article | 850 GBP |
| British Lung Foundation (BLF), London, UK | Travel expenses for representative attending Patient Organisation Advisory Board Meeting and consulting fee paid to organisation | 270 EUR |
| Cittadinanzattiva Onlus, Rome, Italy | Sponsorship of 11th European Patients’ Rights Day | 10,000 EUR |
| European Association for the Study of Diabetes, e.V., Düsseldorf, Germany | Gold Membership/Sponsorship | 10,000 EUR |
| European Cancer Patient Coalition (ECPC), Brussels, Belgium | Sponsorship Annual Meeting 2017 | 10,000 EUR |
| European Federation of Allergy and Airway Diseases Patients Associations (EFA), Brussels, Belgium | Honorarium and travel expenses for representatives participating in disease awareness activities | 1,863 EUR |
| European Federation of Allergy and Airway Diseases Patients Associations (EFA), Brussels, Belgium | Sponsorship to support the EFA's European network | 6,000 EUR |
| European Federation of Associations of Families of People with Mental Illness (EUFAMI), Leuven Belgium | Travel expenses for EUFAMI representatives and representatives of EUFAMI member organisations attending Advisory Board Meeting and consulting fees paid to organisation | 9,533 EUR |
| European Idiopathic Pulmonary Fibrosis & Related Disorders Federation (EU-IPFF), Gentbrugge, Belgium | Gold Sponsorship | 35,000 EUR |
| European Idiopathic Pulmonary Fibrosis & Related Disorders Federation (EU-IPFF), Gentbrugge, Belgium | Sponsorship for Consultation Guide Project 2017 | 160,000 EUR |
| European Idiopathic Pulmonary Fibrosis & Related Disorders Federation (EU-IPFF), Gentbrugge, Belgium | Sponsorship of Awareness Campaign and Website | 39,000 EUR |
| European Idiopathic Pulmonary Fibrosis & Related Disorders Federation (EU-IPFF), Gentbrugge, Belgium | Sponsorship of Written Declaration and Statement | 41,250 EUR |
| European Organisation for Rare Diseases (EURORDIS), Paris, France | Emerald Partnership/Sponsorship 2017 Amendment | 10,000 EUR |
| European Patients Forum (EPF), Brussels, Belgium | Financial Grant Agreement EUPATI Programme | 30,000 EUR |
| Federación Española de Cáncer de Mama (FECMA), Barcelona, Spain | Travel expenses for representative attending Patient Organisation Advisory Board Meeting | 1,060 EUR |
| Federation of European Scleroderma Associations aisbl (FESCA), Tournai, Belgium | Travel expenses for representative participating in panel discussion and consulting fee paid to organisation | 445 EUR |
| Federation of European Scleroderma Associations aisbl (FESCA), Tournai, Belgium | Travel expenses for FESCA representatives and representatives of FESCA member organisations attending Advisory Board Meeting and consulting fees paid to organisation | 10,750 EUR |
| Federation of European Scleroderma Associations aisbl (FESCA), Tournai, Belgium | Travel expenses for representative attending Patient Organisation Advisory Board Meeting and consulting fee paid to organisation | 1,125 EUR |
| Federation of European Scleroderma Associations aisbl (FESCA), Tournai, Belgium | Sponsorship of World Scleroderma Day | 30,000 EUR |
| Federation of European Scleroderma Associations aisbl (FESCA), Tournai, Belgium | Travel expenses for representative attending Patient Organisation Advisory Board Meeting | 74 EUR |
| Global Alliance of Mental Illness Advocacy Networks-Europe (GAMIAN-Europe), Brussels, Belgium | Travel expenses for GAMIAN representatives and representatives of GAMIAN member organisations attending Advisory Board Meeting and consulting fees paid to organisation | 3,802 EUR |
| Global Lung Cancer Coalition (GLCC), Liverpool, UK | Travel expenses for GLCC representatives and representatives of GLCC member organisations attending Advisory Board Meeting | 8,919 EUR |
| Hellenic Pulmonary Fibrosis Association, Argos, Greece | Travel expenses for representative attending Patient Organisation Advisory Board Meeting | 50 EUR |
| Independent Cancer Patients' Voice, London, UK | Travel expenses for representative participating in panel discussion and consulting fee paid to organisation | 1,198 EUR |
| Independent Cancer Patients' Voice, London, UK | Travel expenses for representative attending Patient Organisation Advisory Board Meeting and consulting fee paid to organisation | 1,312 EUR |
| International Diabetes Federation, Brussels, Belgium | Sponsorship Global Partnership | 160,000 EUR |
| International Diabetes Federation, Brussels, Belgium | Sponsorship of the "Life for a Child" Programme | 15,000 EUR |
| Irish Lung Fibrosis Association (ILFA), Dublin, Ireland | Travel expenses for representative attending Patient Organisation Advisory Board Meeting | 665 EUR |
| Irish Lung Fibrosis Association (ILFA), Dublin, Ireland | Travel expenses for representative attending Patient Organisation Advisory Board Meeting and consulting fee paid to organisation | 275 EUR |
| Jedra Udruga oboljelih od raka pluca, Zagreb, Croatia | Travel expenses for representative attending Patient Organisation Advisory Board Meeting | 50 EUR |
| La Ligue contre le Cancer, Saint-Etienne, France | Travel expenses for representative attending Patient Organisation Advisory Board Meeting | 942 EUR |
| Liga Reumatológica Española (LIRE), Madrid, Spain | Travel expenses for representative attending Patient Organisation Advisory Board Meeting and consulting fee paid to organisation | 1,580 EUR |
| Lung Cancer Europe (LuCE), Bern, Switzerland | Travel expenses for LuCE representatives and representatives of LuCE member organisations attending Advisory Board Meeting and consulting fees paid to organisation | 6,135 EUR |
| Lung Cancer Europe (LuCE), Bern, Switzerland | Sponsorship of Annual General Meeting and Lung Cancer Report "Access to treatment report" | 23,000 EUR |
| Lungenfibrose e.V, Essen, Germany | Travel expenses for representatives attending Patient Organisation Advisory Board Meetings and consulting fees paid to organisation | 1,151 EUR |
| Lungenfibrose Forum, Innermanzing, Austria | Travel expenses for representative attending Patient Organisation Advisory Board Meeting and consulting fee paid to organisation | 275 EUR |
| Lupus Europe, Romford, UK | Sponsorship Bronze Package | 10,000 EUR |
| Pulmonary Hypertension Association Bulgaria, Pleven, Bulgaria | Travel expenses for representative attending Patient Organisation Advisory Board Meeting | 209 EUR |
| Stroke Alliance for Europe (SAFE), Bruxelles, Belgium | Sponsorship to support regional conferences for member organisations and scientific stand | 69,000 EUR |
| Stroke Alliance for Europe (SAFE), Bruxelles, Belgium | Sponsorship for educational program “Bringing the patient experience to the Angels Initiative” | 57,754 EUR |
| Stroke Alliance for Europe (SAFE), Bruxelles, Belgium | Sponsorship SAFE/ESO Launch Reception at ESO’s conference in Prague, Czech Republic | 8,000 EUR |
| Stroke Alliance for Europe (SAFE), Bruxelles, Belgium | Sponsorship Launch Event for Burden of Stroke Report at the European Parliament | 5,000 EUR |
| Stroke Association House, London, UK | Sponsorship to support sourcing case studies | 300 GBP |
| The Pulmonary Fibrosis Trust, Staffordshire, UK | Travel expenses for representative attending Patient Organisation Advisory Board Meeting and panel discussion and consulting fee paid to organisation | 1,024 EUR |
| The Pulmonary Fibrosis Trust, Staffordshire, UK | Travel expenses for representative attending Patient Organisation Advisory Board Meeting | 916 EUR |
| TOWARZYSTWO WSPIERANIA CHORYCH NA IPF, Poland | Travel expenses for representative attending Patient Organisation Advisory Board Meeting and consulting fee paid to organisation | 275 EUR |
| Un respiro di speranza, Rome, Italy | Travel expenses for representative attending Patient Organisation Advisory Board Meeting | 454 EUR |
| Union for International Cancer Control (UICC), Geneva, Switzerland | Travel expenses for workshop for World Cancer Day | 1,108 EUR |
| Union for International Cancer Control (UICC), Geneva, Switzerland | Partnership/Sponsorship 2017 | 25,000 USD |
2016
| Name of Patient Organisation | Nature of support | Amount |
|---|---|---|
| Asociación Española de Afectados de Cáncer de Pulmón, Madrid, Spain | Travel expenses for representative attending Patient Organisation Advisory Board Meeting and consulting fee paid to organisation | 1,553 EUR |
| Associazione malati Autoimmuni Orfani, Modena, Italy | Donation in support of the EU IPF Patient Charter's Microsite and the IPF World Week Website and Campaign 2016 | 12,500 EUR |
| Atrial Fibrillation Association, Warwickshire, UK | Consultancy on developing the patient-doctor dialogue tool | 22,000 EUR |
| Belgische verenigung voor longfibrose, Bruges, Belgium | Sponsorship of campaign in support of the IPF Written Declaration | 65,000 EUR |
| Belgische verenigung voor longfibrose, Bruges, Belgium | Travel expenses for representative attending patient organisation panel discussion and consulting fee paid to organisation | 424 EUR |
| Belgische verenigung voor longfibrose, Bruges, Belgium | Sponsorship of the general assembly | 70,000 EUR |
| European Cancer Patient Coalition, Brussels, Belgium | Sponsorship of the general assembly | 10,000 EUR |
| European Federation of Allergy and Airway Diseases Patients Associations, Brussels, Belgium | Corporate Sponsorship (2016/2017) | 60,000 EUR |
| European Idiopathic Pulmonary Fibrosis & Related Disorders Federation, Gentbrugge, Belgium | Sponsorship in support of the development of the ILD Core Network | 50,000 EUR |
| European Idiopathic Pulmonary Fibrosis & Related Disorders Federation, Gentbrugge, Belgium | Sponsorship in support of IPF Workshop | 69,000 EUR |
| European Idiopathic Pulmonary Fibrosis & Related Disorders Federation, Gentbrugge, Belgium | Honorarium for representative participating in Think of Everything Global Patient Survey | 700 EUR |
| European Organisation for Rare Diseases, EU | Membership | 10,000 EUR |
| European Organisation for Rare Diseases, EU | Payment for exhibitor space during the 8th European Conference on Rare Diseases and Orphan Products | 3,000 EUR |
| Federación Española de Ictus, Barceolona, Spain | Sponsorship of International Stroke Patient Meeting | 20,000 EUR |
| Federation of European Scleroderma Associations aisbl, Tournai, Belgium | Travel expenses for representative attending patient organisation panel discussion and consulting fee paid to organisation | 928 EUR |
| Federation of European Scleroderma Associations aisbl, Tournai, Belgium | Travel expenses for FESCA representatives and representatives of FESCA member organisations attending Advisory Board Meeting and consulting fees paid to organisation | 9,461 EUR |
| Federation of European Scleroderma Associations aisbl, Tournai, Belgium | Travel expenses for representative attending patient organisation panel discussion and consulting fee paid to organisation | 761 EUR |
| Federation of European Scleroderma Associations aisbl, Tournai, Belgium | Sponsorship of the Patient Congress - 4th World Systemic Sclerosis Congress | 5,500 EUR |
| Fundación Más Que Ideas, Barcelona, Spain | Travel expenses for representative attending Patient Organisation Advisory Board Meeting and consulting fee paid to organisation | 2,141 EUR |
| Global Lung Cancer Coalition, Liverpool UK | Sponsorship 2015 and 2016 | 60,000 GBP |
| Global Lung Cancer Coalition, Liverpool UK | Travel expenses for representative attending the lounge session during the 24th World Cancer Congress | 285 EUR |
| Independent Cancer Patients' Voice, London, UK | Travel expenses for representative attending Patient Organisation Advisory Board Meeting and consulting fee paid to organisation | 1,679 EUR |
| Landesverband Baden-Württemberg für Lungekrebskranke und deren Angehörige e.V., Heidelberg, Germany | Travel expenses for representative attending Patient Organisation Advisory Board Meeting and consulting fee paid to organisation | 954 EUR |
| Longkanker Nederland, Utrecht, Netherlands | Travel expenses for representative attending Patient Organisation Advisory Board Meeting and consulting fee paid to organisation | 1,242 EUR |
| Lung Cancer Europe, Bern, Switzerland | Travel expenses for representative attending Patient Organisation Advisory Board Meeting and consulting fee paid to organisation | 1,659 EUR |
| Lung Cancer Europe, Bern, Switzerland | Sponsorship of educational programme | 10,000 EUR |
| Lungcancerförbundet Stödet, Stockholm, Sweden | Travel expenses for representative attending patient organisation panel discussion and consulting fee paid to organisation | 1,582 EUR |
| Lungecancerförbundet Stödet, Stockholm, Sweden | Travel expenses for representative attending Patient Organisation Advisory Board Meeting and consulting fee paid to organisation | 1,523 EUR |
| Stroke Alliance for Europe, London, UK | Speaker fee for representative participating in filming session at ESOC Congress | 1,000 GBP |
| Stroke Alliance for Europe, London, UK | 1. Regional SAFE meetings with member organisations 2. SAFE presence with stand at ESO congresses 3. Preparation Burden of Stroke report |
95,000 Euro |
2015
| Name of Patient Organisation | Nature of support | Amount |
|---|---|---|
| Action for Pulmonary Fibrosis, Bury St. Edmunds, UK | Travel expenses for representative attending the IPF Patient Advocacy Group Workshop in Washington | EUR 4,714 |
| Anticoagulation Europe, Bromley, UK | Consultancy fee for media project | GBP 700 |
| Asociación de Familiares y Enfermos de Fibrosis Pulmonar Idiopática, Alcorcón, Spain | Travel expenses for representative attending the IPF Patient Advocacy Group Workshop in Brussels | EUR 598 |
| Association Belge contre la Fibrose Idiopathique Pulmonaire, Brussels, Belgium | Travel expenses for representative attending the IPF Patient Advocacy Group Workshop in Brussels | EUR 110 |
| Asociación Española de Esclerodermia, Madrid, Spain | Travel expenses for representative attending the Patient Organisation Advisory Board Meeting on Systemic Sclerosis | EUR 1,091 |
| Association pour la fibrose pulmonaire idiopathique Pierre ENJALRAN, Ardiège, France | Travel expenses for representative attending the IPF Patient Advocacy Group Workshop in Brussels | EUR 1,291 |
| Atrial Fibrillation Association, Shipston-on-Stour, UK | Sponsorship (global partnership for EU medical advisory committee and patient guide) | GBP 20,000 |
| Atrial Fibrillation Association, Shipston-on-Stour, UK | Consultancy fee for media project | EUR 1,500 |
| Belgische vereniging voor longfibrose, Bruges, Belgium | Travel expenses for representative attending the IPF Patient Advocacy Group Workshop in Brussels | EUR 151 |
| British Lung Foundation, London, UK | Travel expenses for representative attending the IPF Patient Advocacy Group Workshop in Washington | EUR 3,999 |
| Dansk Sklerodermi & Raynaud Forening, Silkeborg, Denmark | Travel expenses for representative attending the Patient Organisation Advisory Board Meeting on Systemic Sclerosis and consulting fee paid to organisation | EUR 1,775 |
| European Cancer Patient Coalition, Brussels, Belgium | Sponsorship of General Assembly | EUR 13,000 |
| European Organisation for Rare Diseases, Paris, France | Emerald sponsorship of the EURORDIS Round Table of Companies | EUR 10,000 |
| European Organisation for Rare Diseases, Paris, France | Travel expenses for representative attending the Patient Organisation Advisory Board Meeting on Systemic Sclerosis | EUR 699 |
| European Patient Forum (fiduciary), Brussels, Belgium | Contribution to the European Patient Academy on Therapeutic Innovation (EUPATI), European Patient Forum acting as fiduciary for EUPATI | EUR 80,000 |
| Gruppo Italiano per la Lotta alla Sclerodermia, Milan, Italy | Travel expenses for representative attending the Patient Organisation Advisory Board Meeting on Systemic Sclerosis and consulting fee paid to organisation | EUR 1,466 |
| Global Lung Cancer Coalition, Liverpool, UK | Sustaining Partner Sponsorship | GBP 30,000 |
| Hengitysliitto ry - harvinaiset hengityssairaudet, Tampere, Finland | Travel expenses for representative attending the IPF Patient Advocacy Group Workshop in Washington | EUR 4,324 |
| Federación Española de Enfermedades Raras, Madrid, Spain | Travel expenses for representative attending the IPF Patient Advocacy Group Workshop in Washington | EUR 2,356 |
| Federation of European Scleroderma Associations aisbl, Tournai, Belgium | Travel expenses for representative attending the Patient Organisation Advisory Board Meeting on Systemic Sclerosis and consulting fee paid to organisation | EUR 1,674 |
| International Diabetes Federation, Brussels, Belgium | Consultancy and communication services on “IntroDia Initiative” | EUR 52,000 |
| LOT- Austria, St. Pölten, Austria | Travel expenses for representative attending the IPF Patient Advocacy Group Workshop in Brussels | EUR 1,673 |
| Lung Cancer Europe, Bern, Switzerland | Membership and sponsorship | EUR 23,000 |
| Lung Cancer Europe, Bern, Switzerland | Sponsorship of LuCE Event in EU Parliament | EUR 10,000 |
| Lungenfibrose e.V., Essen, Germany | Travel expenses for representative attending the IPF Patient Advocacy Group Workshop in Brussels | EUR 1,474 |
| OsservatorioMalattieRare, Rome, Italy | Travel expenses for representative attending the IPF Patient Advocacy Group Workshop in Brussels | EUR 667 |
| Sklerodermie Selbsthilfe e.V., Heilbronn, Germany | Travel expenses for representative attending the Patient Organisation Advisory Board Meeting on Systemic Sclerosis | EUR 768 |
| Stroke Alliance For Europe, London, UK | Sponsorship (global partnership for SAFE regional conferences) | GBP 40,000 |
| The Scleroderma Society, London, UK | Travel expenses for representative attending the Patient Organisation Advisory Board Meeting on Systemic Sclerosis and consulting fee paid to organisation | EUR 1,307 |
| Union for International Cancer Control, Geneva, Switzerland | Sponsorship (Champions Programme Partner) | EUR 25,000 |
| Un Respiro di Speranza, Brescia, Italy | Travel expenses for representative attending the IPF Patient Advocacy Group Workshop in Brussels | EUR 871 |
2014
| Name of Patient Organisation | Nature of support | Amount |
|---|---|---|
| Action for Pulmonary Fibrosis, Bury St. Edmunds, UK | Travel expenses for representative attending IPF Patient Advocacy Group Workshop in Brussels | EUR 728.53 |
| Alzheimer's Disease and Related Disorders Association, Inc., Chicago, USA | Sponsorship of the Alzheimer's Association Research Roundtable | USD 50,000 |
| Anticoagulation Europe, Bromley, UK | Sponsorship | GBP 19,500 |
| Association Belge contre la Fibrose Idiopathique Pulmonaire, Brussels, Belgium | Travel expenses for representatives attending IPF Patient Advocacy Group Workshop in Brussels | EUR 178 |
| Associazione Morgagni per le malattie polmonari, Forlì, Italy | Travel expenses for representative attending IPF Patient Advocacy Group Workshop in Brussels | EUR 1,060.64 |
| Association pour la fibrose pulmonaire idiopathique Pierre ENJALRAN, Ardiège, France | Travel expenses for representative attending IPF Patient Advocacy Group Workshop in Brussels | EUR 841.3 |
| Association Asthme & Allergies, Boulogne Billancourt, France | Consultancy fee and travel expenses for representative to attend patient asthma advisory board meeting in Paris | GBP 1,220.11 |
| Asthma Society of Canada, Toronto, Canada | Consultancy fee and travel expenses for representative to attend patient asthma advisory board meeting in Paris | GBP 4,467.88 |
| Asthma UK, London, UK | Consultancy fee and travel expenses for representative to attend patient asthma advisory board meeting in Paris | GBP 1,246.21 |
| Atrial Fibrillation Association, Shipston-on-Stour, UK | Sponsorship | GBP 20,000 |
| Atrial Fibrillation Association, Shipston-on-Stour, UK | Patient Voice and social media project | GBP 1,113.49 |
| Belgische Vereniging voor longfibrose, Brugge, Belgium | Travel expenses for representative attending IPF Patient Advocacy Group Workshop in Brussels | EUR 89 |
| Canadian Pulmonary Fibrosis Foundation, Markham, Canada | Travel expenses for representative attending IPF Patient Advocacy Group Workshop in Brussels | EUR 4,876.57 |
| Cittadinanzattiva, Rome, Italy | Travel expenses for representative presenting at iHTA congress in Washington DC | EUR 4,525.56 |
| European Association for the Study of Diabetes, Düsseldorf, Germany | Sponsorship (Global Partnership) | EUR 10,000 |
| European Federation of Allergy and Airway Diseases Patients Associations, Brussels, Belgium | Travel expenses for representative to attend patient asthma advisory board meeting in Paris | GBP 537.95 |
| European Organisation for Rare Diseases, Paris, France | Sponsorship of 10th anniversary EURORDIS Gala dinner | EUR 7,500 |
| European Organisation for Rare Diseases, Paris, France | Emerald sponsorship of the EURORDIS Round Table of Companies | EUR 10,000 |
| European Patient Forum (fiduciary), Brussels, Belgium | Contribution to the European Patient Academy on Therapeutic Innovation (EUPATI), European Patient Forum acting as fiduciary for EUPATI | EUR 80,000 |
| Federación Nacional De Asociaciones De Enfermedades Respiratorias, Málaga, Spain | Travel expenses for representative attending IPF Patient Advocacy Group Workshop in Brussels | EUR 600.24 |
| Global Lung Cancer Coalition, Liverpool, UK | Sustaining Partner Sponsorship | GBP 30,000 |
| Hengitysliitto ry - harvinaiset hengityssairaudet, Tampere, Finland | Travel expenses for representative attending IPF Patient Advocacy Group Workshop in Brussels | EUR 1,395.01 |
| HOF, Rishon LeZion, Israel | Travel expenses for representative attending IPF Patient Advocacy Group Workshop in Brussels | EUR 850.89 |
| International Diabetes Federation, Brussels, Belgium | Sponsorship (Global Partnership) | EUR 160,000 |
| International Diabetes Federation, Brussels, Belgium | Sponsorship of the "Life for a Child" Programme | EUR 15,000 |
| International Diabetes Federation, Brussels, Belgium | Consultancy and communication services on "IntroDia Initiative" | EUR 130,000 |
| Japan Allergy Tomono Kai, Tokyo, Japan | Consultancy fee and travel expenses for representative to attend patient asthma advisory board meeting in Paris | GBP 5,369.60 |
| Leukämiehilfe Rhein-Main e.V. 1991, Rüsselsheim, Germany | Sponsoring des Patienten und Angehörigen Forum (01.11.2014) | EUR 500 |
| Lung Cancer Europe, Bern, Switzerland | Membership and sponsorship | EUR 20,000 |
| Lungenfibrose e.V., Essen, Germany | Travel expenses for representatives attending IPF Patient Advocacy Group Workshop in Brussels | EUR 2,251.77 |
| National Asthma Council of Australia, South Melbourne, Australia | Consultancy fee and travel expenses for representative to attend patient asthma advisory board meeting in Paris | GBP 6,664.24 |
| National Psoriasis Foundation, Portland, USA | Charitable donation | USD 2,500 |
| Österreichische Lungenunion, Vienna, Austria | Consultancy fee and travel expenses for representative to attend patient asthma advisory board meeting in Paris | GBP 1,299.07 |
| Pulmonary Fibrosis Foundation, Chicago, USA | Travel expenses for representative attending IPF Patient Advocacy Group Workshop in Brussels | EUR 1,578.9 |
| Stroke Alliance For Europe, London, UK | Sponsorship | GBP 40,000 |
| The Max Foundation, Seattle, USA | Sponsorship of scientific educational program "Max Global Helpline" | USD 12,000 |
| Union for International Cancer Control, Geneva, Switzerland | Sponsorship (Champions Programme Partner) | USD 50,000 |
| World Hepatitis Alliance, Geneva, Switzerland | Donation of Exhibition Booth to WHA for use during the European Association for the Study of the Liver Congress | Non-financial contribution |
2013
| Name of Patient Organisation | Nature of support | Amount |
|---|---|---|
| Alzheimer's Disease and Related Disorders Association, Inc., Chicago, USA | Sponsorship of the Alzheimer's Association Research Roundtable | USD 50,000 |
| Anticoagulation Europe, Bromley, UK | Support of A Guide to NOACs | EUR 23,206 |
| Anticoagulation Europe, Bromley, UK; Arrythmia Alliance, Stratford-upon-Avon, UK; Atrial Fibrillation Association, Shipston-on-Stour, UK; StopAfib, Greenwood, USA |
Multimedia Series : A New Era in Anticoagulation | EUR 11,100 |
| Arrythmia Alliance, Stratford-upon-Avon, UK Atrial Fibrillation Association, Shipston-on-Stour, UK StopAfib, Greenwood, USA |
Honoraria for 2 TweetChats (May and August 2013) about Atrial Fibrillation | EUR 3,300 |
| Atrial Fibrillation Association, Shipston-on-Stour, UK | Support of Atrial Fibrillation Association country specific websites | EUR 24,160 |
| European AIDS Treatment Group, Brussels, Belgium | Support of policy and advocacy work-science and research | EUR 76,000 |
| European Cancer Patient Coalition, Brussels, Belgium | Sustaining Partnership Sponsor | EUR 30,000 |
| European Federation of Allergy and Airway Diseases Patients Associations, Brussels, Belgium | BI Corporate Sponsorship | EUR 12,000 |
| European Liver Patients Association, Sint-Truiden, Belgium | Support the education and patient support efforts | EUR 80,000 |
| European Patient Forum (fiduciary), Brussels, Belgium | Contribution to the European Patient Academy on Therapeutic Innovation (EUPATI), for which the European Patient Forum is acting as fiduciary | EUR 70,000 |
| European Society for Medical Oncology, Lugano, Switzerland | Sponsorship of the 2012 ESMO Patient Advocacy Track | EUR 25,000 |
| Forum Lungenkrebs Schweiz, Basel, Switzerland | Sponsorship of the “Facing Lung Cancer” Art Exhibition at the 2012 European Lung Cancer Congress in Geneva, Switzerland. | EUR 7,400 |
| Global Lung Cancer Coalition, Liverpool, UK | Sustaining Partner Sponsorship | GBP 30,000 |
| International COPD Coalition | Corporate Sponsorship Grant | USD 30,000 |
| International Diabetes Federation, Brussels, Belgium | Sponsorship (Global Partnership) | EUR 160,000 |
| International Diabetes Federation, Brussels, Belgium | Sponsorship of the “Life for a Child” Programme | EUR 20,000 |
| Lung Foundation Australia, Milton, Australia | Unrestricted educational grant to support the Australian IPF Registry. | EUR 15,000 |
| Stroke Alliance For Europe, London, UK | Support of regional congresses | EUR 11,825 |
| Union for International Cancer Control, Geneva, Switzerland | Sponsorship (Champions Programme Partner) | USD 25,000 |
| Women Against Lung Cancer Europe, Orbassano, Italy | Sponsorship | EUR 15,000 |
| World Hepatitis Alliance, Geneva, Switzerland | Support of policy and advocacy work across the Global Advocacy network | EUR 150,000 |
Contacting Us
You can send us your query and feedback via E-mail.
-
Our Company
As a family-owned company Boehringer Ingelheim is governed by the Board of Managing Directors composed of six members. Read more about their respective responsibilities.